Clinical Trials Browser

Phase 1 × High-Risk Resectable NSCLC × durvalumab × Clear all

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Phase 1 Completed

High-Risk Resectable NSCLC